Important Notice for Geron Corporation Shareholders
New York, NY, March 20, 2025 – The Gross Law Firm, a leading securities fraud class action law firm, notifies investors that a class action lawsuit has been filed against Geron Corporation (GERN) in the United States District Court for the Northern District of California. The lawsuit alleges violations of the Securities Exchange Act of 1934 by Geron and certain of its top executives.
Class Period and Eligibility
The class period for this action is from February 1, 2023, to November 1, 2024. Shareholders who purchased or acquired Geron securities during this period are encouraged to contact the firm as soon as possible to discuss their legal rights and potential appointment as lead plaintiff in this action.
Allegations Against Geron
The complaint alleges that Geron and its executives made false and misleading statements regarding the company’s financial condition and business prospects. Specifically, the complaint alleges that the defendants failed to disclose adverse information regarding the company’s financial performance and its ability to generate revenue from its therapeutics, including its lead product, Imetelstat.
Potential Impact on Individual Investors
If Geron is found to have engaged in securities fraud, shareholders who purchased or acquired the company’s securities during the class period may be able to recover their losses through this class action. The exact amount of damages will depend on the specific facts and circumstances of each case.
- Shareholders who suffered significant losses due to their investments in Geron during the class period may be eligible to join the class action and potentially recover their losses.
- Shareholders who held larger positions in Geron during the class period may have a greater potential for recovery.
- Shareholders who wish to learn more about their legal rights and potential eligibility for the class action are encouraged to contact The Gross Law Firm as soon as possible.
Potential Impact on the World
The outcome of this lawsuit could have significant implications for the biotech industry as a whole. Should the allegations be proven true, it could lead to increased scrutiny of other companies in the industry and potentially lead to increased transparency and accountability.
Moreover, the lawsuit could have a negative impact on investor confidence in the biotech sector, potentially leading to decreased investment and reduced research and development efforts in the field.
Contact Information
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests, please contact The Gross Law Firm by emailing the lead counsel, Brian Gross, at [email protected], calling (212) 582-0658, or visiting our website at
Conclusion
The filing of this class action against Geron Corporation is a reminder to all investors to remain vigilant and to carefully consider the information provided by companies and their executives before making investment decisions. The Gross Law Firm is committed to fighting for the rights of shareholders and ensuring that companies are held accountable for any securities fraud or misrepresentations.
If you purchased or acquired Geron securities during the class period and believe you may have a claim, we encourage you to contact us as soon as possible to discuss your legal rights and potential eligibility for the class action. Together, we can hold Geron and its executives accountable for any wrongdoing and potentially recover losses for affected shareholders.
